Screener
Tarsus Pharmaceuticals, Inc. TARS Total Operating Expenses
Discontinued — last reported Q4 '23
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 27, 2024.
- Filed
- Feb 27, 2024
- Fiscal year
- FY2023
- Accession
- 0001819790-24-000018
| Line item | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|
| Cost of license fees and collaboration revenue | — | 955 |
| Research and development | 50,312 | 42,624 |
| Selling, general and administrative | 108,700 | 44,949 |
| Total operating expenses | 160,605 | 88,528 |
| Loss from operations | (143,158) | (62,712) |
| Other income (expense): | ||
| Interest income | 10,337 | 3,499 |
| Interest expense | (3,346) | (2,199) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s total operating expenses?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total operating expenses of $40.15M in Q4 2023.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude